Cargando…

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration‐resistant prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, David, Mateo, Joaquin, Stenzinger, Albrecht, Rojo, Federico, Shiller, Michelle, Wyatt, Alexander W, Penault‐Llorca, Frédérique, Gomella, Leonard G, Eeles, Ros, Bjartell, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185363/
https://www.ncbi.nlm.nih.gov/pubmed/33630412
http://dx.doi.org/10.1002/cjp2.203
_version_ 1783704775893712896
author Gonzalez, David
Mateo, Joaquin
Stenzinger, Albrecht
Rojo, Federico
Shiller, Michelle
Wyatt, Alexander W
Penault‐Llorca, Frédérique
Gomella, Leonard G
Eeles, Ros
Bjartell, Anders
author_facet Gonzalez, David
Mateo, Joaquin
Stenzinger, Albrecht
Rojo, Federico
Shiller, Michelle
Wyatt, Alexander W
Penault‐Llorca, Frédérique
Gomella, Leonard G
Eeles, Ros
Bjartell, Anders
author_sort Gonzalez, David
collection PubMed
description Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration‐resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC to identify those who can benefit from targeted therapies. Best practice guidelines in overall biospecimen collection and processing for molecular analysis are widely available for several tumour types. However, there is no standard protocol for molecular diagnostic testing in prostate cancer. Here, we provide a series of recommendations on specimen handling, sample pre‐analytics, laboratory workflow, and testing pathways to maximise the success rates for clinical genomic analysis in prostate cancer. Early involvement of a multidisciplinary team of pathologists, urologists, oncologists, radiologists, nurses, molecular scientists, and laboratory staff is key to enable optimal workflow for specimen selection and preservation at the time of diagnosis so that samples are available for molecular analysis when required. Given the improved outcome of patients with mCRPC and homologous recombination repair gene alterations who have been treated with PARP inhibitors, there is an urgent need to incorporate high‐quality genomic testing in the routine clinical pathway of these patients.
format Online
Article
Text
id pubmed-8185363
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-81853632021-06-15 Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer Gonzalez, David Mateo, Joaquin Stenzinger, Albrecht Rojo, Federico Shiller, Michelle Wyatt, Alexander W Penault‐Llorca, Frédérique Gomella, Leonard G Eeles, Ros Bjartell, Anders J Pathol Clin Res Review Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration‐resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC to identify those who can benefit from targeted therapies. Best practice guidelines in overall biospecimen collection and processing for molecular analysis are widely available for several tumour types. However, there is no standard protocol for molecular diagnostic testing in prostate cancer. Here, we provide a series of recommendations on specimen handling, sample pre‐analytics, laboratory workflow, and testing pathways to maximise the success rates for clinical genomic analysis in prostate cancer. Early involvement of a multidisciplinary team of pathologists, urologists, oncologists, radiologists, nurses, molecular scientists, and laboratory staff is key to enable optimal workflow for specimen selection and preservation at the time of diagnosis so that samples are available for molecular analysis when required. Given the improved outcome of patients with mCRPC and homologous recombination repair gene alterations who have been treated with PARP inhibitors, there is an urgent need to incorporate high‐quality genomic testing in the routine clinical pathway of these patients. John Wiley & Sons, Inc. 2021-02-25 /pmc/articles/PMC8185363/ /pubmed/33630412 http://dx.doi.org/10.1002/cjp2.203 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Gonzalez, David
Mateo, Joaquin
Stenzinger, Albrecht
Rojo, Federico
Shiller, Michelle
Wyatt, Alexander W
Penault‐Llorca, Frédérique
Gomella, Leonard G
Eeles, Ros
Bjartell, Anders
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title_full Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title_fullStr Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title_full_unstemmed Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title_short Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
title_sort practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185363/
https://www.ncbi.nlm.nih.gov/pubmed/33630412
http://dx.doi.org/10.1002/cjp2.203
work_keys_str_mv AT gonzalezdavid practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT mateojoaquin practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT stenzingeralbrecht practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT rojofederico practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT shillermichelle practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT wyattalexanderw practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT penaultllorcafrederique practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT gomellaleonardg practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT eelesros practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer
AT bjartellanders practicalconsiderationsforoptimisinghomologousrecombinationrepairmutationtestinginpatientswithmetastaticprostatecancer